Europe Cervical Cancer Diagnostic Market By Test Type & Geography - Analysis & Forecast - ResearchAndMarkets.com

DUBLIN--()--The "Europe Cervical Cancer Diagnostic Market & Forecast, By Test Type (Pap smear and HPV DNA), Countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway and Netherlands)" report has been added to ResearchAndMarkets.com's offering.

Cervical cancer is one of the most serious public health issues in Europe. Despite introduction of vaccination in 21 European countries, still more than 23 Thousand women have died from cervical cancer across all over Europe.

Cervical cancer incidence rate in Europe was 10.2 per 100,000 women population. Germany, France and United Kingdom are top three dominating countries in the Europe cervical cancer market in 2017. Cervical cancer generally occurs in women over 30 years. It is mostly caused by the Human papillomavirus (HPV) virus. Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences.

Increasing cervical cancer incidence rate is one of the key factors that drive the cervical cancer screening market. Rapidly increasing female population, growing prevalence of HPV infections and increasing awareness about cervical cancer screening programs is also expected to drive the cervical cancer screening market in the near future.

Country Coverage:

  • United Kingdom
  • France
  • Germany
  • Italy
  • Spain
  • Sweden
  • Switzerland
  • Norway
  • Netherlands

Key Topics Covered:

1. Executive Summary

2. Europe Cervical Cancer Test (Screening) Analysis

3. Market & Population Share - By Countries

4. United Kingdom - Cervical Cancer Test Analysis

5. France - Cervical Cancer Test Analysis

6. Germany - Cervical Cancer Test Analysis

7. Italy - Cervical Cancer Test Analysis

8. Spain - Cervical Cancer Test Analysis

9. Sweden - Cervical Cancer Test Analysis

10. Switzerland - Cervical Cancer Test Analysis

11. Norway - Cervical Cancer Test Analysis

12. Netherlands - Cervical Cancer Test Analysis

13. Growth Drivers

14. Challenges

For more information about this report visit https://www.researchandmarkets.com/research/vgzvhh/europe_cervical?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Diagnostics, In Vitro Diagnostics

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Diagnostics, In Vitro Diagnostics